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Significance {#sec1}
============

**There are three known clonally transmissible cancers in nature: CTVT, the Tasmanian devil facial disease, and leukemias of clams. CTVT is the only one that regresses, spontaneously or after vincristine administration, providing a unique model for cancer regression in general. By performing systematic genome-wide analysis of CTVT regression, we found that treatment with vincristine induces host innate immune genes and epithelial differentiation, triggering immune-rejection of the tumor. Gene expression changes correlate with demethylation of specific intragenic regions. Our results provide a unique insight into the molecular and immunological mechanisms driving cancer regression and support recently proposed models whereby innate immunity plays a critical role in triggering cancer rejection.**

Introduction {#sec2}
============

The canine transmissible venereal tumor (CTVT) is a contagious cancer allograft ([@bib3], [@bib13], [@bib40]). Remarkably, CTVT is able to evade host immune-detection, allowing its worldwide spread in dogs ([@bib3], [@bib40]).

First described in the nineteenth century ([@bib5], [@bib45]), the tumor grows mostly on male and female external genitalia and it is naturally transmitted between dogs by coitus, biting, or licking tumor-affected areas ([@bib40]). CTVT can be transplanted experimentally between dogs and even to other members of the *Canidae* family ([@bib9]). The similarity of the karyotype observed in CTVT samples from distant geographical areas suggested that this tumor originated from a common ancestor ([@bib14], [@bib21]). A LINE element insertion into the MYC locus present in CTVTs but not in the host dogs supported this notion ([@bib24]). More recently, the clonal origin of CTVT was proven by analysis of microsatellite polymorphisms, mtDNA, and by dog leukocyte antigen (DLA) typing ([@bib43], [@bib53]), and confirmed by genome-wide sequencing ([@bib42]). Together with the Tasmanian devil facial tumor disease ([@bib3]) and the recently described leukemia-like cancer in soft-shell clams ([@bib34], [@bib35]), CTVT is a naturally occurring transmissible cancer of clonal origin.

CTVT was the first tumor to be experimentally transplanted before the era of inbred mice ([@bib45]). Experimentally transplanted CTVT is clinically characterized by a progressive (P), a stationary (S), and a regressive (R) phase ([@bib11]). In the P phase, there is rapid growth of the tumor to become a pedunculated, cauliflower-like exudative mass. Microscopically there is abundance of mitotic cancer cells and few infiltrating lymphocytes. In the S phase, growth slows considerably; there are fewer cancer cells in mitosis, and more apoptotic cells and infiltrating lymphocytes. In the R phase, there are abundant infiltrating lymphocytes, cancer cells disappear, the tumor stroma collapses, and there is collagen deposition ([@bib8], [@bib39]). Recovered dogs are immune to re-inoculation ([@bib9]). In naturally occurring CTVT, spontaneous regression is also observed, albeit less frequently than in transplanted CTVT ([@bib49]). However, natural CTVT is often sensitive to radiotherapy and chemotherapy and even a single treatment may induce regression ([@bib17], [@bib68]).

Histology of tumors in the P and R phases indicated that regression is characterized by apoptosis of cancer cells and the presence of tumor-infiltrating lymphocytes (TILs) ([@bib17], [@bib49]) with production of anti-tumor immunoglobulin Gs ([@bib11]). Thus complete regression seems to depend on an appropriate immune response, a notion supported by the fact that immunosuppressed dogs and puppies develop more aggressive CTVT that lacks TILs and is rarely eliminated ([@bib73]).

It is not clear how CTVT evades immune-detection during transmission and growth but triggers rejection in the R phase. In transplanted CTVT, a model has been proposed whereby secretion of transforming growth factor β (TGF-β) by cancer cells suppresses class I and II DLA expression and NK (natural killer) cell activity. TGF-β is counteracted by interleukin-6 (IL-6), produced by TILs, hence, when a critical threshold is reached, TGF-β is overcome by IL-6, resulting in re-expression of DLAs on CTVT cells and their rapid elimination ([@bib7], [@bib20]). There is little evidence, however, that this mechanism operates in natural CTVT.

Although the natural spread of CTVT is confined to dogs, humans and dogs share many forms of cancer with similar clinical presentation, pathology, and genetic mutations, including osteosarcoma, soft tissue sarcoma, non-Hodgkin lymphomas, and melanoma ([@bib57]). This suggests that understanding regression of CTVT could be important in identifying potential mechanisms of regression in human cancers. To understand the process leading to CTVT regression, we analyzed biopsies from natural CTVTs collected before and after treatment with vincristine and contrasted cases that fully regressed to cases that did not regress.

Results {#sec3}
=======

We collected three serial biopsies from two naturally occurring tumors, one in a male (CTVT-5) and one in a female (CTVT-6) mixed breed dog ([Table 1](#tbl1){ref-type="table"}). The dogs were treated with a single intravenous administration of 0.025 mg/kg vincristine. The first biopsy was collected pre-therapy; the second and third biopsies were collected 6 and 14 days post-therapy, respectively. Macroscopically, both pre-therapy CTVTs were large (\>3 cm diameter), cauliflower-like, ulcerated, and bleeding ([Figure S1](#mmc1){ref-type="supplementary-material"}). Both CTVTs responded to vincristine, becoming smaller with reduced bleeding. However, at the time of the third biopsy, CTVT-5 had almost completely regressed, whereas CTVT-6 still presented a significant tumor mass ([Figure S1](#mmc1){ref-type="supplementary-material"}). Biopsies were examined microscopically to count mitotic figures, TILs, granulocytes, and apoptotic cells ([Table 1](#tbl1){ref-type="table"}). The most striking difference between the two samples was the lack of TILs in CTVT-6, whereas in CTVT-5 TILs represented 3.4% of total cell count in the first biopsy and 15.6% in the second biopsy. Both samples contained 15%--20% of apoptotic cells in the second biopsy, increasing to \>80% in CTVT-5 but remaining stable in CTVT-6. Based on the macroscopic appearance and the histology, we classified the CTVT-5 serial biopsies as P, S, and R phases and the CTVT-6 biopsies as P, P/S, and S, respectively. A third case in a male mixed breed dog (CTVT-17) ([Table 1](#tbl1){ref-type="table"}; [Figure S1](#mmc1){ref-type="supplementary-material"}) presented at a different clinic after the first two cases and a biopsy was collected at day 0, and days 22 and 48 post-vincristine. Clinical examination indicated that the biopsy taken at day 22 was S phase and biopsy taken at day 48 was R phase. Poorer tissue preservation prevented pathological analysis of CTVT-17.Table 1Histopathology on Tissue Sections of CTVT-5 and CTVT-6CTVT Sample, Day (Biopsy Number)Sex of DogCTVT PhaseMitosis/1.000 CellsLymphocytes (%)Granulocytes (%)Apoptotic/Necrotic Cells (%)5, day 0 (biopsy 1)maleP2.43.402.7005, day 6 (biopsy 2)S/R015.60NA16.305, day 14 (biopsy 3)R0NANA806, day 0 (biopsy 1)femaleP4.708.8606, day 6 (biopsy 2)P/S010206, day 14 (biopsy 3)S0102017[a](#tblfn1){ref-type="table-fn"} day 0 (biopsy 1)malePNA[b](#tblfn2){ref-type="table-fn"}NANANA17[a](#tblfn1){ref-type="table-fn"} day 22 (biopsy 2)SNANANANA17[a](#tblfn1){ref-type="table-fn"} day 48 (biopsy 3)S/RNANANANA[^2][^3]

RNA-Seq Identifies Genes Differentially Regulated in S and R Phases {#sec3.1}
-------------------------------------------------------------------

To gain a deeper understanding of the mechanisms of CTVT regression, we sought to identify specific genes and pathways that are differentially expressed in the serial biopsies. We reasoned that genes driving regression would be differentially regulated in P versus S or R phase. We also sought to determine if epigenetic regulation of gene expression might be important. Therefore, we performed transcriptome and methylome analyses in parallel to match differentially regulated and differentially methylated genes and conducted gene pathway analysis to identify key host-CTVT interactions. CTVT-6 provided an important control because it did not regress. Our approach is summarized in [Figure 1](#fig1){ref-type="fig"}.Figure 1Diagram of the Experimental Pipeline Used to Study CTVT Regression

Nucleic acids were extracted from biopsies and total RNA was prepared for sequencing following the Illumina TruSeq mRNA protocol and sequenced on an Illumina NextSeq to yield an average of 15 million reads per sample. RNA extracted from CTVT-17 did not pass quality control and could not be sequenced. Following alignment and removal of PCR duplicates, we applied rigorous generalized linear models for all of the differential gene expression analyses, modeling count data using the negative binomial distribution via the BioConductor library DESeq and using a matrix (regression status, CTVT, time point before and after treatment), which allows to incorporate paired data into multifactorial analysis ([@bib1], [@bib16]) ([Table S1](#mmc2){ref-type="supplementary-material"}). We compared changes in gene expression occurring in each sequential biopsy; a total of 6,756 genes were found differentially regulated (2-fold or more). To better capture changes likely to be of biological significance, we applied two stringent cutoffs, requiring a fold-change (FC) \> 10 and an adjusted p value (adj-p) \< 0.01 (Benjamini-Hochberg test). Using this filter, we detected 1,016 differentially expressed genes, of which 704 were upregulated and 312 downregulated ([Table S1](#mmc2){ref-type="supplementary-material"}).

Expression analysis ([Figure 2](#fig2){ref-type="fig"}A; [Table S2](#mmc3){ref-type="supplementary-material"}) revealed that some genes were already upregulated in the second biopsy, while others were upregulated in the third biopsy. For CTVT-6, both the first and second biopsies were more similar to the P phase of CTVT-5 than to the S phase, whereas the third biopsy was more similar to the S phase of CTVT-5 ([Figure 2](#fig2){ref-type="fig"}A). Downregulated genes progressively faded in CTVT-5 but not in CTVT-6 ([Figure 2](#fig2){ref-type="fig"}A). These findings agreed with the lack of clinical regression and the pathology of CTVT-6 ([Table 1](#tbl1){ref-type="table"}; [Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 2Transcriptional Profiling Detects a Signature of CTVT Regression(A) Heatmap showing differential expression of the 1,016 significant genes (FC \> 10 and adj-p \< 0.01) relative to the geometric mean of CTVT-5 B1 and CTVT-6 B1 (mean of the logs). Genes are sorted by expression of B3/geometric mean of (CTVT-5 B1, CTVT-6 B1). B1, first biopsy; B2, second biopsy; B3, third biopsy.(B) qPCR on DNA extracted from biopsies obtained before (B1, day 0) and after (B2, day 28) vincristine administration of the 7xx CTVTs. Specific primers were used to amplify LINE-MYC DNA (tumor specific), *DLA DQA-1* (tumor specific), and *DLA DQA-1* (common to both host and tumor). All quantifications are relative to β-actin.(C) Heatmap showing differential expression of the 1,350 significant genes in the 7xx CTVTs (FC \> 10 and adj-p \< 0.01) relative to the geometric mean of the five B1 samples. Genes are sorted by expression of B2/geometric mean of 7xx B1s. Each row represents an individual gene. RNA-seq data were not available for CTVT-774 B1. The red lines next to each row indicate genes that reached statistical significance in the R-B2/R-B1 versus NR-B2/NR-B1 comparison.(D) Venn diagram showing the degree of overlap between CTVT-5 R versus P genes (1,016 genes), the 7xx CTVTs B2 versus B1 genes (1,350 genes) and genes that reached statistical significance in the R-B2/R-B1 versus NR-B2/NR-B1 comparison (189 genes).See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

To confirm and extend the RNA sequencing (RNA-seq) results, we investigated six additional CTVT cases (CTVT-7xx) acquired by natural transmission, three of which regressed (CTVT-765, -766, and -772) and three of which did not (CTVT-761, -774, and -775) following treatment with vincristine. Due to ethical and practical constraints, biopsies from these CTVTs were collected before treatment (biopsy 1 or B1) and at day 28 after vincristine (biopsy 2 or B2); hence they did not have the same temporal resolution of CTVT-5 and CTVT-6. Nonetheless, these samples were collected years apart from CTVT-5 and CTVT-6, on a different continent and were sequenced in a different laboratory, and thus can be considered as a completely independent experiment to validate key results.

To confirm the clinical observations, DNA from these 7xx CTVTs was analyzed by qPCR to measure the LINE-Myc insertion, a hallmark of this tumor ([@bib24]), as well as a region of MHC class II *DLA DQA-1* shared between CTVT and host and a region of *DLA DQA-1* specific for CTVT ([@bib43]). CTVT-765, -766, and -772 regressed clinically and showed loss of LINE-Myc DNA and tumor-specific *DLA DQA-1*. In contrast, CTVT-761 and -774 did not regress clinically and maintained LINE-Myc and tumor-specific *DLA DQA-1* ([Figure 2](#fig2){ref-type="fig"}B). CTVT-775 also did not regress clinically but showed some loss of LINE-Myc and tumor-specific *DLA DQA-1* ([Figure 2](#fig2){ref-type="fig"}B).

RNA from these samples was sequenced to yield between 18 and 31.5 million reads per sample, except B 1 of CTVT-774, which did not pass quality controls and was not included in the subsequent analysis. Principal-component analysis revealed a clear separation between B1 and B2 of the 7xx regressing tumors but not for the biopsies of non-regressing CTVTs ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). To examine the overall reproducibility of the experiments, we compared log~2~FC in gene expression in B3/B1 of CTVT-5 with the mean log~2~FC in B2/B1 of the regressive or non-regressive 7xx CTVTs. Considering all expressed genes, correlation (Pearson\'s coefficient) was 0.80 for the regressive CTVTs ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D), rising to 0.94 when considering only those genes that passed the FC \> 10 adj-p \< 0.01 cutoff, indicating high reproducibility.

In the regressive 7xx CTVTs, 1,350 genes were differentially regulated in B2 relative to B1 (FC \> 10 and adj-p \< 0.01), but only 59 genes met these cutoffs in the non-regressive 7xx CTVTs ([Table S1](#mmc2){ref-type="supplementary-material"}). Expression analysis of these 1,350 genes revealed a pattern of expression changes similar to CTVT-5 and CTVT-6, which discriminated between regressing and non-regressing tumors ([Figure 2](#fig2){ref-type="fig"}C). The overlap between significantly changed genes in CTVT-5 (B3/B1) and in the regressive 7xx CTVTs (B2/B1) was 63.7% (648/1,016 genes) ([Figure 2](#fig2){ref-type="fig"}D). Further analysis of the 1,350 genes significantly changed in the regressive 7xx CTVTs identified 189 genes that were also statistically significantly different (p \< 0.05) when comparing changes in their expression levels (B2/B1) in regressive versus non-regressive 7xx CTVTs (regressive \[R\]-B2/R-B1 versus non-regressive \[NR\]-B2/NR-B1) ([Figure 2](#fig2){ref-type="fig"}C, red lines on the right; [Table S2](#mmc3){ref-type="supplementary-material"}). Of these 189 genes, 127 genes were also differentially expressed (FC \> 10 adj-p \< 0.01) in CTVT-5 but not in CTVT-6, thus forming a potential "core" signature of regression: they reproduce across experiments and are statistically significantly different between regressing and non-regressing tumors within the second experiment ([Figure 2](#fig2){ref-type="fig"}D; [Table S2](#mmc3){ref-type="supplementary-material"}). Overall, these data indicated the existence of a signature of regression, which we sought to explore in greater depth.

Inflammation and Epithelial Cell Proliferation Characterize the Early Response to Vincristine {#sec3.2}
---------------------------------------------------------------------------------------------

The CTVT-5 expression analysis revealed dynamic changes in gene expression and we hypothesized that this may reflect sequential steps ultimately leading to CTVT regression. We therefore examined the temporal nature of the changes in gene expression ([Figure 3](#fig3){ref-type="fig"}A). We classified genes into several groups based on when they reached an FC \> 10 (at the adj-p \< 0.01 cutoff): we found 150 "early up" genes (upregulated \[\>10-fold\] in S phase relative to P phase), 203 "late up" or "late down" genes (up- or downregulated \[\>10-fold\] in R relative to S, but not in S relative to P), and 663 "progressive" genes (progressively up- or downregulated \[\>10-fold\] in R relative to P, but not in R relative to S, or S relative to P) ([Figures 3](#fig3){ref-type="fig"}A and 3B).Figure 3Dynamic Changes in Gene Expression across Sequential Biopsies Identify Pathological Processes during CTVT Regression(A) Schematic depiction of the changes in expression for the early, progressive, and late genes in the different CTVT phases. The dotted line indicates an expression FC \> 10 relative to baseline values in the P phase.(B) Venn diagram illustrating the overlap between differentially expressed genes across all three comparisons. The diagram explains how differentially expressed genes were classified into three categories: early, late, and progressive.(C) Pie charts indicating the relative proportion of IPA gene networks within the early, progressive, and late upregulated gene groups of CTVT-5 and their relative proportion within the regressing 7xx CTVTs.(D and E) Heatmaps of comparative IPA analyses showing the top 30 diseases and biofunction pathways (ex cancer) (D) or canonical pathways (E) for B1, B2, and B3 of CTVT-5 and each individual regressive 7xx CTVTs. Pathways are clustered based on significance (−log10 p value, Fisher\'s exact test) and similarity.See also [Table S3](#mmc4){ref-type="supplementary-material"}.

Differentially expressed genes corresponding to these three different temporal profiles were studied in each CTVT for pathway enrichment using Ingenuity Pathway Analysis (IPA) ([www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity){#intref0010}) ([Figures 3](#fig3){ref-type="fig"}C--3E). Individual IPA profiles were compared based on statistical significance (Fisher\'s exact test) and similarity ([Figure 3](#fig3){ref-type="fig"}C; [Table S3](#mmc4){ref-type="supplementary-material"}). In CTVT-5, the top early networks were related to recruitment of, and invasion by, granulocytes, agranulocytes, and leukocytes, formation and inflammation of skin, as well as a broader "cancer" signature. This was followed by proliferation and activation of lymphocytes, NK cells, and B cells. The late stage was characterized by upregulation of networks related to migration and invasion of cells in general, proliferation of connective tissue, and migration of vascular endothelial cells suggesting formation of new tissue ([Figures 3](#fig3){ref-type="fig"}C--3E; [Table S3](#mmc4){ref-type="supplementary-material"}). These pathways were shared between CTVT-5 and the regressive 7xx CTVTs ([Figures 3](#fig3){ref-type="fig"}C--3E; [Table S3](#mmc4){ref-type="supplementary-material"}).

IPA showed an enrichment within the early up gene group for genes involved in skin inflammation, epithelial cell differentiation and development, and cell migration (p \< 0.01, Fisher\'s exact test) ([Table S3](#mmc4){ref-type="supplementary-material"}). Key genes in these early networks that were also differentially expressed in the regressive 7xx CTVTs (FC \> 10 and adj-p \< 0.01; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}) included *TP63*, which is required for epithelial and keratinocyte differentiation ([@bib10], [@bib65]), as well as keratins such as *KRT4* (FC = 92) and *KRT15* (FC = 104), which are expressed in the basal layer of stratified epithelia ([@bib37]) ([Figure 4](#fig4){ref-type="fig"}A). Overall, within this group, the overlap between CTVT-5 and the regressing 7xx CTVTs was 78% (42/54 genes) ([Table S4](#mmc5){ref-type="supplementary-material"}). There was a prominent skin inflammatory component in the network, classified by IPA as psoriasis and Netherton syndrome, a disease characterized by chronic inflammation and dermal infiltrate of eosinophils and neutrophils ([@bib26]) ([Figure 4](#fig4){ref-type="fig"}A). Key early up genes involved in inflammation included *S100A8* (FC = 18) and *S100A9* (FC = 14), which are endogenous TLR4 ligands ([@bib71]), *PIGR* (FC = 560), which mediates transport of IgA across mucosal epithelial cells ([@bib23]), as well as the chemotactic cytokine *CCL5* (FC = 11) ([Figure 4](#fig4){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}).Figure 4Early Upregulation of Epithelial and Inflammation-Related Genes Characterizes CTVT Regression(A) IPA diagram showing gene networks of early upregulated genes in CTVT-5. Inflammation-related nodes are highlighted in red. (B) Scatterplot illustrating correlation between normalized RNA-seq counts for early upregulated genes in CTVT-5 (B2) and CTVT-6 (B3). Best-fit line is shown in red.(C and D) Gene expression levels of *CCL5* and *CCL28* in CTVT-5 and CTVT-6 (C), and in the additional 7xx CTVT samples (D) (mean ± SEM, n = 3). Significant adj-p values are shown (^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01): all have FC \> 10.See also [Table S4](#mmc5){ref-type="supplementary-material"}.

To identify possible early drivers of regression, we plotted normalized RNA reads of early up genes of CTVT-5, which regressed, versus CTVT-6, which did not regress. *CCL5* was among the most prominent outliers ([Figure 4](#fig4){ref-type="fig"}B). CCL5/RANTES is a key chemokine, which, by binding to its receptor CCR5, promotes chemotaxis of monocytes, T lymphocytes, NK cells, eosinophils, and basophils, and can be produced by epithelial cells and keratinocytes ([@bib28], [@bib52]). *CCL28* (FC = 30 in CTVT-5 and 3 in CTVT-6) was another prominent outlier ([Figure 4](#fig4){ref-type="fig"}C; [Table S1](#mmc2){ref-type="supplementary-material"}). These chemokine genes also reached higher expression levels in the regressive relative to the non-regressive 7xx CTVTs and high absolute levels ([Figure 4](#fig4){ref-type="fig"}D). The relative change in *CCL5* expression was significantly different between regressive and non-regressive CTVTs (R-B2/R-B1 versus NR-B2/NR-B1, p \< 0.01), whereas *CCL28* reached statistical significance in the regressive CTVTs only ([Figure 4](#fig4){ref-type="fig"}D). CCR5 signaling was among the most significant canonical pathways identified by IPA in the regressive 7xx CTVTs ([Figure 3](#fig3){ref-type="fig"}E; [Table S3](#mmc4){ref-type="supplementary-material"}). Furthermore, *CCL5* was one of four early up genes in the core signature of regression, the others being *CD8*, *MFAP4*, which also promotes monocytes chemotaxis ([@bib58]), and *UBASH3A*, a member of the T cell ubiquitin ligand family ([Table S2](#mmc3){ref-type="supplementary-material"}). Thus *CCL5* might be important to trigger rejection.

Immune Cell Infiltration, Cell-Cycle Arrest, and Tissue Remodeling Characterize the Secondary Response to Vincristine {#sec3.3}
---------------------------------------------------------------------------------------------------------------------

Next we focused on the prominent immunological network detected by IPA in all the regressive CTVTs. A group of 88 immunological genes was significantly upregulated in CTVT-5, but not in CTVT-6, with a good overlap of individual genes between CTVT-5 and the regressive 7xx CTVTs (≈60% overlap at FC ≥ 10 and adj-p \< 0.01) but a 0% overlap with the non-regressive CTVTs at the same cutoff ([Figure 5](#fig5){ref-type="fig"}A; [Table S4](#mmc5){ref-type="supplementary-material"}). These genes formed networks, which included CCR5 signaling, leukocyte extravasation, and T, NK, and B cell function ([Figure 5](#fig5){ref-type="fig"}B; [Table S3](#mmc4){ref-type="supplementary-material"}).Figure 5Upregulation of T, NK, and B Cell-Related Genes Characterizes the Secondary Response to Vincristine(A) Expression changes in B1, B2, or B3 of 88 progressive immunological genes in CTVT-5 and CTVT-6.(B) Diagram showing 10 representative nodes obtained by IPA using the 88 progressive immunological genes upregulated in CTVT-5. Key nodes are shown in blue; key genes belonging to the core signature of regression are shown in red; progressive up genes in common between CTVT-5 and the regressive 7xx CTVTs are shown in purple.(C) The 88 immunological genes were annotated manually using Genecards and the available literature into four groups: I, inflammation/innate immunity; T, T cells; NK, natural killer cells; and B, B cells. Fold upregulation of genes in the S and R phase is relative to the P phase and is based on the normalized RNA-seq reads.See also [Tables S4](#mmc5){ref-type="supplementary-material"}, [S5](#mmc6){ref-type="supplementary-material"}, and [S6](#mmc7){ref-type="supplementary-material"}.

We classified these immunological genes into four groups based on the existing literature and available experimental evidence: genes involved in inflammation, T cell function, NK cell function, and B cell quantity or function ([Figure 5](#fig5){ref-type="fig"}C; [Table S4](#mmc5){ref-type="supplementary-material"}). Inflammation-related genes were the most upregulated in the S phase and were further upregulated in the R phase. T cell- and NK cell-related genes were progressively upregulated. B cell genes, albeit less prominent in quantity and expression levels, were also progressively upregulated ([Figure 5](#fig5){ref-type="fig"}C), in agreement with pathological studies reporting infiltration of CTVT by B cells ([@bib49]) and the presence of a B cell signature in acute allograft rejection ([@bib55]).

To further validate key pathways, we performed IPA using the 189 genes that reached statistical significance in the R-B2/R-B1 versus NR-B2/NR/B1 comparison for the 7xx CTVTs or the 127 genes forming the core regressive signature ([Figure 2](#fig2){ref-type="fig"}D; [Table S2](#mmc3){ref-type="supplementary-material"}). We compared these IPAs with those obtained with each regressive CTVT. This analysis confirmed that granulocyte/agranulocyte adhesion and diapedesis, communication between innate and adaptive immunity, T cell signaling, and CCR5 signaling were the most significant upregulated pathways across all datasets ([Table S5](#mmc6){ref-type="supplementary-material"}).

To better understand the contribution of the host and the tumor to the changes in gene expression, we took advantage of several sources of information regarding tissue origin. Firstly, deep sequencing of the CTVT genome revealed that 657 genes were deleted or had a premature stop codon in CTVT ([@bib42]) ([Table S1](#mmc2){ref-type="supplementary-material"}), hence they could be used as markers of host tissue. Secondly, the CTVT genome has accumulated over two million mutations ([@bib42]), which we could use to map a particular gene to host or CTVT, provided that the sequencing depth was sufficient and that at least two mutations were present within a particular transcript. Using this filter, we sampled 63 upregulated genes that passed the FC \> 10 adj-p \< 0.01 cutoff in CTVT-5 and were also involved in key IPA networks, including skin inflammation. The analysis showed that almost all of them were of host origin ([Table S6](#mmc7){ref-type="supplementary-material"}), indicating that the host stroma contributes to CTVT regression.

We found no early downregulated genes and instead found 177 progressive genes downregulated in CTVT-5 relative to CTVT-6. The main functional networks affected were cell cycle, DNA replication and recombination, and organ development ([Figure 6](#fig6){ref-type="fig"}A; [Table S3](#mmc4){ref-type="supplementary-material"}). The large cell-cycle network included many genes involved in the formation of the mitotic spindle, condensation, and segregation of chromosomes ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B; [Table S7](#mmc8){ref-type="supplementary-material"}). This is consistent with the inhibitory effect of vincristine on microtubule dynamics, leading to perturbation of the mitotic spindle and cell-cycle arrest ([@bib44]). These genes remained unchanged in CTVT-6, confirming the specificity of the effect ([Figure S3](#mmc1){ref-type="supplementary-material"}A; [Table S7](#mmc8){ref-type="supplementary-material"}). Notably, the cell-cycle gene network was not detected in the regressive 7xx CTVTs ([Figure 6](#fig6){ref-type="fig"}A; [Table S3](#mmc4){ref-type="supplementary-material"}), suggesting that the dramatic changes in cell cycle occurred early and were missed in the second biopsy of the regressive 7xx CTVTs, which was collected 28 days after vincristine treatment.Figure 6Downregulated Genes Show a Melanoma-like Signature(A) Pie charts indicating the relative proportion of each functional IPA network within the progressive and late downregulated gene groups of CTVT-5 and within the downregulated gene groups of the regressing 7xx CTVTs. Note that no early downregulated gene was detected in CTVT-5.(B) Plots showing the confidence value of the main functionally annotated pathways identified by IPA for the late downregulated gene group in each regressing CTVT. The p value (Fisher\'s exact test) for each pathway is shown on the x axis.(C and D) Heatmaps of comparative IPA analyses showing the top 10 diseases and biofunction pathways (C) or canonical pathways (D) for each individual regressive CTVTs. Pathways are clustered based on significance (Fisher\'s exact test) and similarity.See also [Tables S7](#mmc8){ref-type="supplementary-material"} and [S8](#mmc9){ref-type="supplementary-material"}; [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Pathway Analysis on Genes that Cease to Be Expressed during Regression Suggests that CTVT May Be Similar to Melanoma {#sec3.4}
--------------------------------------------------------------------------------------------------------------------

The late downregulated genes were only detected in CTVT-5 and not in CTVT-6, suggesting that they were closely linked to advanced tumor regression ([Table S1](#mmc2){ref-type="supplementary-material"}). The third biopsy of CTVT-5, collected at 14 days after vincristine administration, contained 80% necrotic or apoptotic cells ([Table 1](#tbl1){ref-type="table"}). We took advantage of this fact to investigate the possible cell or tissue of origin of CTVT. We reasoned that genes that disappeared in the last biopsy were more likely to belong to CTVT (except for immunological genes), and hence could be used to obtain a transcriptional profile of the tumor itself. There were 135 genes downregulated in the late stage. The IPA functional networks with the higher confidence were related to solid cancers ([Figure 6](#fig6){ref-type="fig"}B), and within these groups melanoma had the highest confidence and a large number of genes (80 genes, p = 1.22 × 10^−8^) ([Figures 6](#fig6){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}; [Table S3](#mmc4){ref-type="supplementary-material"}). Remarkably, IPA of downregulated genes in the regressive 7xx CTVTs also showed that the functional networks with the highest confidence and greatest number of genes were skin cancer and cutaneous melanoma (\>180 genes, p \< 1.52^−17^) ([Figure 6](#fig6){ref-type="fig"}B; [Table S3](#mmc4){ref-type="supplementary-material"}). The top three IPA disease pathways identified across all CTVTs were skin cancer, cutaneous melanoma, and melanoma ([Figure 6](#fig6){ref-type="fig"}C). Furthermore, skin cancer and cutaneous melanoma emerged as the most significant downregulated disease and biofunctions pathways within the core signature of 127 genes and across all datasets ([Table S8](#mmc9){ref-type="supplementary-material"}).

Although the highly significant cancer signature was expected, the melanoma signature was not, given that CTVT has been proposed have a histiocytic origin ([@bib9], [@bib38]). The histological classification of CTVT was mainly based on positive immunostaining for lysozyme (encoded by *LYZ*), α1-antitrypsin (encoded by *SERPINA1*), and vimentin (encoded by *VIM*) in about 30%--50% of the tumor cells ([@bib38]). However, our RNA-seq analysis ([Table S1](#mmc2){ref-type="supplementary-material"}) showed no significant change in the expression levels of *LYZ* (Ensembl ID: ENSCAFG00000000426), *SERPINA1* (Ensembl ID: ENSCAFG00000017646), or *VIM* (Ensembl ID: ENSCAFG00000004529) in any regressing CTVTs, hence it is unlikely that such markers are specific for the tumor, although we note that histamine biogenesis was a prominent canonical pathway ([Figure 6](#fig6){ref-type="fig"}D).

To explore this issue further, we assessed the relative enrichment of our late downregulated gene signature in the human NCI-60 cancer cell line panel originating from other solid tumors ([@bib50]). We found that melanoma was among the most enriched tumor cell types, and that this showed the most significant difference when compared with all other solid tumors in the panel ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). Thus we concluded that CTVT has similarities to melanoma at the transcriptional level.

DNA Methylation Changes during CTVT Regression {#sec3.5}
----------------------------------------------

Next we investigated whether changes in gene expression were associated with epigenetic modifications. DNA methylation at CpG islands in promoters often causes silencing of genes and, conversely, their demethylation stimulates gene expression ([@bib4], [@bib12]). However, it was also shown that methylation occurs in other DNA regions, such as CpG island shores within 2 kb of transcriptional start site and even within exons near the 3′ end of genes ([@bib19], [@bib29]). Methylation of such regions appears to impact on gene expression more strongly than CpG island methylation ([@bib19]). Therefore, we conducted a global methylation analysis using MeDIP-seq ([@bib67]) on the sequential biopsies of CTVT-5, CTVT-6, and CTVT-17, and mapped methylation levels within the promoter, the first exon, the first intron, internal exons, internal introns, the last exon, and the 3′ end of genes. We then matched the methylation pattern for each gene with our transcriptional data (RNA-seq) to correlate methylation levels and location to gene expression. We maintained the same overall classification based on when genes were up- or downregulated (early, progressive, and late). To detect specific changes, we normalized the signal by subtracting the methylation values of genes that were not expressed in any of the biopsies. Although we were unable to perform transcriptional analysis on CTVT-17, we observed consistent methylation profiles across all biopsies for each gene list obtained from RNA-seq of CTVT-5 and CTVT-6 ([Figures 7](#fig7){ref-type="fig"}, [S5](#mmc1){ref-type="supplementary-material"}A, and S5B).Figure 7Changes in Gene Expression Correlate with Specific Changes in DNA MethylationDemethylation profiles of early (A), progressive (B), and late (C) upregulated genes across serial biopsies of CTVT-17 (red), CTVT-5 (yellow), and CTVT-6 (green). Demethylation scores were obtained for individual genes by quantifying demethylation levels within specific regions of genes (≤2 kb upstream of first exon; first exon; first intron; internal exons; internal introns; last exon; ≤2 kb downstream of last exon) and normalized by subtracting the corresponding demethylation values observed for non-expressed genes. Boxplots illustrate the variation within these values across each gene-list (boxes extend to the first and third quartile, whiskers extend to 1.5× inter-quartile range, and the line represents median values). For each CTVT sample, boxplots are in order (from left to right): first, second and third biopsy.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

In the early upregulated genes we observed demethylation at the first exon across all CTVT samples. This demethylation pattern was sustained in CTVT-5 and CTVT-17, but was reduced in the third biopsy of CTVT-6 ([Figure 7](#fig7){ref-type="fig"}A). A more complex demethylation pattern was observed in the late upregulated genes. Here internal exons and the last exon showed either progressive or sustained demethylation, from the first to the last biopsy. The exception was CTVT-6, whose demethylation levels dropped in the third biopsy. Demethylation was weaker in the progressive upregulated genes, presumably because the over-represented immunological genes did not change their methylation patterns ([Figure 7](#fig7){ref-type="fig"}B).

Hypermethylation was found in downregulated genes. This was more pronounced for the progressive downregulated genes ([Figure S5](#mmc1){ref-type="supplementary-material"}). In CTVT-5 and CTVT-17, the internal and last exons showed progressive hypermethylation. In CTVT-6, the internal exon showed no progressive change in methylation, whereas the last exon showed hypermethylation in the first and second biopsies, which was fainter in the third biopsy ([Figure S5](#mmc1){ref-type="supplementary-material"}). Thus CTVT-6 may be initially epigenetically permissive for changes in gene expression important for regression but this condition is not stable. These results support the hypothesis that epigenetic changes play a significant role in vincristine-induced regression of CTVT. Because most upregulated genes were of host origin, it seems likely that epigenetic changes in stroma and host tissue surrounding the tumor were critical to induce regression.

Discussion {#sec4}
==========

CTVT is unique among naturally transmissible cancers because it can regress ([@bib9], [@bib13]). Although spontaneous regression is uncommon, a single dose of vincristine or radiation is often sufficient to cure this cancer in a few weeks ([@bib17]). This suggests that CTVT is particularly susceptible to changes that break tolerance to this cancer; however, a comprehensive analysis of the events leading to regression of natural CTVT was lacking.

To this end we compared tumors that regressed with tumors that did not regress to investigate mechanisms of CTVT regression by transcriptional and methylation profiling. We observed that differential expression of many genes occurred in parallel with changes in the pathology, revealing a stepwise process that begins with a strong inflammatory response and epithelial and keratinocyte proliferation, followed by immune infiltration of T, NK, and B cells, and arrest in the cell cycle. Ultimately, in regressing CTVT, there is loss of tumor cells, cell migration, and tissue remodeling. This process has similarities with wound healing ([@bib66]), as [@bib39] noted in their histochemical study of CTVT.

The early phase was characterized by a strong and reproducible upregulation of genes involved in epithelial cell and keratinocyte differentiation, including many keratins (*KRT4 KRT13, KRT15, KRT23, KRT78,* and *KRT80*) and epithelia-specific transcription factors such as *TP63* ([@bib33], [@bib48]). This suggested that mucosal and/or skin remodeling is one of the first responses characterizing the transition from the P to S phase CTVT. Since keratins were mostly of host origin, we propose that proliferation of keratinocytes and epithelial stem cells of the basal layer is an attempt by the surrounding tissue to contain or replace the malignant tissue. However, these genes were not found in the core signature of regression, suggesting that epithelial cell and keratinocyte differentiation is necessary but not sufficient to trigger regression and may also be associated with the S phase.

Within the early upregulated genes, we detected a significant number of genes involved in inflammation. Expression of genes involved in interferon signaling (*IRF7, ISG15,* and *IFIT1*) was higher in all regressive CTVTs relative to non-regressive CTVTs, suggesting activation of the innate immune response ([@bib59]). Furthermore, among the most upregulated early genes were chemotactic cytokines *CCL5* and *CCL28* ([@bib64]). *CCL5* was statistically significantly upregulated in the regressive CTVTs only; it was one of four early upregulated genes in the core gene signature of regression, and IPA identified CCR5 signaling as one of the most significant canonical pathways consistently detected across regressing CTVTs. CCL5 recruits dendritic cells, monocytes, and lymphocytes ([@bib70]), whereas CCL28, expressed by epithelial cells, is a mucosal-specific cytokine that recruits lymphocytes and eosinophils ([@bib46]).

Keratinocytes can express many chemokines ([@bib64]), therefore we propose that their activation and the concomitant tissue inflammation result in further enhanced production of certain chemokines. We propose that, when *CCL5* expression reaches a certain threshold, CTVT regression becomes likely. This is consistent with the notion that, whereas low chronic inflammation has a pro-tumor effect, a dramatic increase in the production of inflammatory mediators by the local host cells induces a switch from chronic to florid inflammation, which triggers infiltration by immune cells ([@bib31]). In our case, the initial strong inflammatory response may be induced by vincristine, which causes the release of damage-associated molecular patterns from stressed or dying cells ([@bib25]). Because CTVT is an allograft, substantial, chemokine-mediated recruitment of alloreactive T cells into the tumor should induce direct recognition of foreign DLA molecules, triggering acute rejection ([@bib25]). In this scenario, low-dose chemotherapy or radiotherapy, far from causing immunosuppression, would in fact elicit inflammation and trigger a cascade of events ultimately leading to CTVT regression.

Thus, our results support the idea of combining low-dose chemotherapy with immune checkpoint therapy to shift the balance toward an acute inflammatory response that may trigger cancer regression in humans ([@bib15], [@bib31], [@bib36], [@bib60]). Cancers that have accumulated many mutations, such as CTVT ([@bib42]), may produce many neo-antigens and be more prone to rejection ([@bib18]).

Our correlative transcriptome and methylome analysis indicated that most changes in gene expression (up or down) were associated with changes in methylation at particular sites, suggesting that epigenetic mechanisms were at play in eliciting regression. Indeed, epigenetic regulation of MHC-I expression has been reported in the Tasmanian devil facial tumor disease ([@bib61]). In agreement with previous reports, we found that methylation changes affecting gene expression were clustered around the first exon, internal exons, and the last exon, whereas changes at promoter CpG islands were less frequent ([@bib19], [@bib29]). It is notable that the non-regressing CTVT-6 showed a trend toward re-methylation in the last biopsy, which suggests that the demethylation of upregulated genes needs to be maintained over time for successful regression. Further work is required to understand what causes this re-methylation in CTVT-6. Because most upregulated genes appeared to be of host origin, the methylation analysis points to a critical epigenetic remodeling of host tissue surrounding the tumor and possibly stroma cells.

Previous reports suggested that CTVT was histiocytic on the basis of immunohistochemical detection of lysozyme, α1-antitrypsin and vimentin in about 30%--50% of the tumor cells ([@bib32], [@bib38]). However, our transcriptome analysis did not detect expression changes of these genes at any stage in any of the CTVT samples (although we note that histamine biogenesis was a prominent canonical pathway identified by IPA across all regressive CTVTs). The third biopsy of CTVT-5 demonstrated advanced regression and almost complete loss of the tumor mass. Because we had serial biopsies available, we reasoned that genes whose expression was profoundly downregulated or lost from the second to the third biopsy in CTVT-5 would provide a "signature" of CTVT. Skin cancer and cutaneous melanoma were the most highly significant networks identified by IPA across all CTVTs on the basis of the downregulated genes. Analysis of the core signature of regression also confirmed this result, which was further tested by independently assessing the relative enrichment of this gene signature in the NCI-60 human cancer cell line panel originating from other solid tumors ([@bib50]). Caution is required though, because our analysis was not performed on isolated CTVT cells and our interpretation rests on the assumption that the particular gene signature was mainly due to the loss of tumor rather than host cells. Despite these limitations, our result seems plausible because melanocytic and non-melanocytic melanoma can form on the genital mucosa ([@bib51]); hence, as it would be suitably accessible for venereal transmission, melanoma was previously shown to be transplantable across individuals ([@bib56]) and it can occasionally regress due to its intrinsic immunogenicity ([@bib47]). Furthermore, MHC-II expression can be induced in CTVT and melanoma ([@bib22], [@bib43]), where it is associated with an inflammatory signature and a superior response to anti-PD1 antibody therapy ([@bib22]). Melanoma and the Tasmanian devil\'s facial tumor are both neural crest-derived cancers ([@bib41], [@bib62]), which raises the intriguing possibility that some transmissible cancers share a common origin.

In conclusion, our genome-wide scale and systematic analysis of CTVT regression has provided important new information on the interplay between chemotherapy, the host tissue, the host innate and acquired immune system, and the tumor, which may be applicable in understanding regression of human and animal cancers.

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**anti-5-methylcytosine antibodyDiagenodeC15200006-100**Biological Samples**CTVT biopsies (see [STAR Methods](#sec5){ref-type="sec"} for details)Department of Veterinary Sciences, University of Messina, Italy and Veterinary Hospital "Dr Halim Atique" - Centro Universitário de Rio Preto (UNIRP), São José do Rio Preto, São Paulo, BrazilN/A**Chemicals, Peptides, and Recombinant Proteins**Vincristine (Italy)\
Vincristine (Brazil)Teva Italia\
Libbs038549010\
7896094202870LidocaineZoetis100319019Proteinase K (ChIP grade)DiagenodeC06050002**Critical Commercial Assays**SYBR® Green MixLifeTechnologies/Thermo Fisher4309155DNAse I kitThermo FisherAM1906High-Capacity cDNA Reverse Transcription KitApplied Biosystems/Thermo Fisher4368814QuantiTect SYBR Green RT-PCR KitQiagen204243AmpureXT magnetic beadsAutoQ BiosciencesAQ 60050Illumina TruSeq RNA Library Prep kit v2IlluminaRS-122-2001KAPA Stranded mRNA-Seq KitKAPA BioscienceKK8420Auto-MeDIP kitDiagenodeAF-Auto01-0016End repair moduleNew England BiolabsE6050LA-tail moduleNew England BiolabsE6053LAdapter ligation moduleNew England BiolabsE6056LMESA BLUE qPCR MasterMix PlusEurogentecRT-SY2X-03+WOUBHigh-fidelity Phusion polymerase (5×)New England BiolabsM0530LdNTP mixNew England BiolabsN0447L**Deposited Data**RNAseq for CTVT-5 and CTVT-6This paperArrayExpress\
[E-MTAB-5488](array-express:E-MTAB-5488){#intref0015}RNAseq for 7xx CTVTsThis paperArrayExpress\
[E-MTAB-5889](array-express:E-MTAB-5889){#intref0020}MeD-IPThis paperArrayExpress\
[E-MTAB-5495](array-express:E-MTAB-5495){#intref0025}CTVT genome 1[@bib42]European Nucleotide Archive\
SAMEA2358413CTVT genome 2[@bib42]European Nucleotide Archive\
SAMEA2358415Cancer cells transcriptomesArrayExpress[E-GEOD-32474](array-express:E-GEOD-32474){#intref0030}**Oligonucleotides**β-ACTIN Forward: CTCCATCATGAAGTGTGACGTTG[@bib43]N/Aβ-ACTIN Reverse: CGATGATCTTGATCTTCATTGTGC[@bib43]N/ADLA DQA-1 tumour. Forward: GAATTTGATGGCGATGAGTT[@bib43]N/ADLA DQA-1 tumour Reverse: TCAGGATGTTCAAGTTTTGT\
TTTAT[@bib43]N/ADLA DQA-1 common. Forward ACTACGGCATAAATGTCTA\
CCAGTC[@bib43]N/ADLA DQA-1 common Reverse: CAAGTTTCTCAGTGCAC\
CCTGT[@bib43]N/ALINE-MYC Forward: AGGGTTTCCCATCCTTTAACATT[@bib43]N/ALINE-MYC Reverse: AGATAAGAAGCTTTTGCACAGCAA[@bib43]N/APE.Adapter.1.0:\
ACACTCTTTCCCTACACGACGCTCTTCCGATC^∗^T\
(^∗^) = phosphothiolate modificationThis PaperN/APE.Adapter.2.0: \[Phos\]GATCGGAAGAGCGGTTCAGCA\
GGAATGCCGAG\
\[Phos\] = 3′phosphate groupThis PaperN/AMethylated qPCR Forward:\
GGTGAACTTCCGATAGTGThis PaperN/AMethylated qPCR Reverse: CAGTCATAGATGGTCGGTThis PaperN/AUnmethylated Forward: GTTAGAGCCTGCATAACGThis PaperN/AUnmethylated Reverse:\
GAAAGAGCACTGGCTAACThis PaperN/APCR_primer_PE_1.0:\
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCT\
ACACGACGCTCTTCCGATC^∗^T;\
(^∗^) = phosphothiolate modificationThis PaperN/APCR_primer_PE_2.0: CAAGCAGAAGACGGCATACGAGA\
TCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATC^∗^T\
\[Phos\] = 3′phosphate groupThis PaperN/A**Software and Algorithms**Ingenuity Pathway Analysis (IPA®)Qiagen[www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity){#intref0035}MEV software suiteTM4 MeV<http://www.tm4.org/mev.html>PicardToolsBroad Institute<http://broadinstitute.github.io/picard/>HTSeq-count[@bib2]<http://www-huber.embl.de/users/anders/HTSeq>TopHat v2.0.13[@bib69]<https://ccb.jhu.edu/software/tophat/index.shtml>R/BioConductor[@bib16]<https://www.bioconductor.org/>MeDUSA[@bib72]<https://www.ucl.ac.uk/cancer/research/department-cancer-biology/medical-genomics-group/past-projects/medusa-project/medusa>DESeq BioConductor library[@bib1]<https://bioconductor.org/packages/release/bioc/html/DESeq.html>DESeq2 BioConductor library[@bib30].<http://bioconductor.org/packages/release/bioc/html/DESeq2.html>

Contact for Reagent and Resource Sharing {#sec5.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Ariberto Fassati (<a.fassati@ucl.ac.uk>).

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Dogs {#sec5.3.1}

CTVT biopsies were collected from 9 dogs as detailed below:SampleAge of Dog (Years)SexBreedLocationYear of CollectionSite of TumorTreatmentCTVT-53MMixedMessina (Italy)2009PenisVincristine 2 sessionsCTVT-64FMixedMessina (Italy)2009VestibulumVincristine 2 sessionsCTVT-175MMixedReggio Calabria (Italy)2009PenisVincristine 2 sessionsCTVT-7615FMixedSão José do Rio Preto (Brazil)2012VaginaVincristine 6 sessionsCTVT-7654FBorder-CollieSão José do Rio Preto (Brazil)2012VulvaVincristine 7 sessionsCTVT-7667FShih TzuSão José do Rio Preto (Brazil)2012VaginaVincristine 4 sessionsCTVT-7725MMixedSão José do Rio Preto (Brazil)2013PenisVincristine 6 sessionsCTVT-7744MMixedSão José do Rio Preto (Brazil)2013NoseVincristine 8 sessionsCTVT-7753MBorder-CollieSão José do Rio Preto (Brazil)2013PenisVincristine 7 sessions

Biopsies of CTVT-5 and CTVT-6 were collected from dogs undergoing diagnostic assessment at the Department of Veterinary Sciences, University of Messina, Italy. Biopsy of CTVT-17 was collected at a kennel in Reggio Calabria, Italy. Biopsies of CTVT-761, 765, 766, 772, 774 and 775 were collected at the Veterinary Hospital "Dr Halim Atique" - Centro Universitário de Rio Preto (UNIRP), São José do Rio Preto, São Paulo, Brazil. All the procedures on animals treated in Italy were in agreement with welfare and ethics European directives and were approved by the University of Messina, under protocol number ORME07PFLB. All the procedures carried out in Brazil were approved by the Animal Research Ethics Committee of the São Paulo State University at Jaboticabal, São Paulo, Brazil, under protocol number 24674/2012. All dogs were in good health at the time of the consultation. Diagnosis of CTVT was done by means of visual inspection of the tumor and evaluation of size, morphology and location, followed by cytological smears, stained with May-Grünwald Giemsa. Apoptotic cells and infiltrating cells were counted manually. Biopsies were collected by surgical excision, after local infiltrations of lidocaine, frozen in liquid N~2~ and processed for histology and immunohistochemistry. Dogs with confirmed CTVT were treated as follows: CTVT-5 and 6, vincristine sulfate 0.025 mg/Kg iv once and biopsies were collected at day 0 (before treatment), day 6 and day 14 after treatment; CTVT-17: 0.025 mg/Kg iv vincristine sulfate once and biopsies collected at day 0, 22, and 48 after treatment; CTVT-761, 765, 766, 772, 774, 775, vincristine sulfate 0.5 mg/m^2^ iv at weekly intervals and biopsies collected at day 0 (before treatment) and at day 28 after the third dose of vincristine.

Method Details {#sec5.4}
--------------

### RNAseq {#sec5.4.1}

Nucleic acids were extracted from biopsy 1 (pre-therapy), biopsy 2 (day 6 after vincristine) and biopsy 3 (day 14 after vincristine) of CTVT-5 and CTVT-6; from biopsy 1 (pre-therapy), biopsy 2 (day 22 after vincristine) and biopsy 3 (day 48 after vincristine) of CTVT 17 and from biopsy 1 (pre-therapy) and biopsy 2 (day 28 - after the third dose of vincristine) of CTVT-761, 765, 766, 772, 774, 775 using Qiagen RNAeasy Blood & Tissue kit following the manufacturer's instructions.

For CTVT-5, CTVT-6 and CTVT-17, 250 ng of total RNA was prepared for sequencing following the Illumina TruSeq mRNA (unstranded) protocol with insert size 150-250, multiplexed, and sequenced (V2 High Output kit, 54bp PE) on an Illumina Nextseq to yield an average of \> 15 million reads per sample. Data was de-multiplexed using bcl2fastq v 2.16. Read QC reports were generated in Illumina Basespace. FASTQ files passing read QC were analyzed on the WTSI genomics cluster using an in house pipeline (Python/R). Sequencing reads were aligned to Canfam 2.0 reference genome using TopHat v2.0.13 ([@bib69]); GTF files describing genes features were obtained from the Ensembl website (<http://www.ensembl.org/info/data/ftp/index.html>). Duplicate reads were then removed using PicardTools (<http://broadinstitute.github.io/picard/>) /) and read counts per gene generated using HTSeq-count (<http://www-huber.embl.de/users/anders/HTSeq>).

For CTVT-761, 765, 766, 772, 774, 775, 1 μg of total RNA was prepared for sequencing following the KAPA Stranded mRNA-Seq Kit (KAPA Bioscience) protocol with insert size 150-250, multiplexed, and sequenced (V2 High Output kit, 54bp PE) on an Illumina Nextseq to yield an average of \> 10 million reads per sample. RNAseq analysis, data were de-multiplexed using bcl2fastq v 2.17. Paired end reads were mapped to dog transcriptome reference sequence Canfam 2.0 to make it directly comparable with CTVT 5 and 6. Mapping and generation of read counts per gene were done using Kallisto ([@bib6]).

### SNP Mapping {#sec5.4.2}

Integrative Genomic Viewer (IGV) was used to visualize mapped reads from CTVT samples and two published CTVTs (Accession numbers: [SAMEA2358413](ncbi-mga:SAMEA2358413){#intref0100} and [SAMEA2358415](ncbi-mga:SAMEA2358415){#intref0105}, downloaded from the ENA) and to manually inspect SNPs ([@bib54]).

### Quantitative PCR for Genomic DNA {#sec5.4.3}

qPCR to detect CTVT and host DNA in CTVT-761, 765, 766, 772, 774 and 775 was performed using an Applied Biosystems 7900HT Fast Real-Time PCR system in a final volume of 20 μL using SYBR® Green Mix (Life Technologies), 20 ng genomic DNA and 5 μM primers as described in the [Key Resources Table](#sec5.1){ref-type="sec"}. Cycling parameters were 95°C, 10 min for 1 cycle followed by 95°C, 15 s and 60°C, 60 s for 40 cycles. Standard curves for *LINE-MYC*, *ACTB*, *DLA DQA-1* tumor and *DLA DQA-1* common were generated using a CTVT sample. Relative *LINE-MYC*, *ACTB*, *DLA DQA-1* (tumor) and *DLA DQA-1* (common) amplification values were estimated for each sample using the standard curve. Each qPCR was performed in triplicate. Values were normalized against a standard curve that was generated for each primer set using CTVT tumour 29T sample as reference, which was previously characterized ([@bib42]). This linear standard curve was generated from a range of known relative DNA concentrations of 29T, which could be used to calibrate each qPCR reaction and calculate the relative amount of DNA input. Relative DNA input for *LINE-MYC, DLA DQA-1* tumor and *DLA DQA-1* common was then normalized to *ACTB*. The relative standard curve was generated according to the Guide to performing relative quantitation of gene expression using real-time quantitative PCR -- Applied Biosystems (Carlsbad, California, USA).

### Methylome {#sec5.4.4}

Methylated DNA Immunoprecipitation (MeDIP)-seq was performed using 600 ng genomic DNA from biopsies 1, 2 and 3 of CTVT-5, CTVT-6 and CTVT-17. DNA was sonicated on a Diagenode Bioruptor (4 x 15 min cycles set to high intensity) to produce a median fragment length of 180--230 and verified using a 2100 Bioanalyzer with DNA1000 chips (Agilent; p/n 5067-1504). Sample DNA was prepared for next-generation sequencing as follows:

Firstly, DNA was end repaired: reagents (NEBNext End Repair Enzyme mix: 5 μl; NEBNext End Repair Reaction Buffer (10X): 10 μl; Fragmented DNA: 85 μl) were mixed on ice in a sterile PCR tube and incubated in a thermocycler at 20°C for 30 min. The reaction was placed on ice after incubation then spun briefly in a microfuge for ∼10 s to collect condensate. Next the reaction was purified with Ampure XP purification beads: end-repaired DNA and 1.8× volumes of magnetic beads were added to a clean 1.5 ml microcentrifuge tube, pipette mixed to homogenize and allow DNA to bind to magnetic beads. The mixture was incubated at room temperature for 5 min then placed on a magnetic rack to collect beads/DNA. Supernatant was aspirated off and discarded. Next, 200 μl 70% ethanol was added to the beads and left for 30 s. Supernatant was aspirated off and discarded. Repeat ethanol wash. Leaving the samples in magnetic rack, the magnetic rack was placed in oven for 10-15 min to evaporate residual ethanol. When beads looked drab, the sample was taken off the magnetic rack and 37 μl Tris-HCl was added to liberate DNA from beads. The mixture was gently pipette mixed and incubated for 1 min. The sample was placed back on the magnetic rack to separate the beads. Supernatant was aspirated off and carried to the dA- Tailing step. Following purification, DNA was dA- tailed: reagents (Klenow Fragment (3'→5' exo-): 3 μl; NEB Next dA-tailing Reaction Buffer (10X): 5 μl; water: 5 μl; purified DNA: 37 μl) were mixed on ice in a sterile PCR tube and incubated in a thermal cycler at 37°C for 30 min. Following incubation the samples were purified with Ampure XP purification beads and eluted in 25 μl Tris-HCl for the next step.

Next, paired-end sequencing adapters were added: reagents (Quick T4 DNA Ligase:5 μl; Quick Ligation Reaction Buffer (5x): 10 μl; paired-end sequencing adapters \[PE.Adapter.1.0 and PE.Adapter.2.0\]: 10 μl; purified DNA: 25 μl) were mixed on ice in a sterile PCR tube and incubated in a thermocycler at 18°C for 15 min. Following incubation the samples were purified with Ampure XP purification beads and eluted in 25 μl Tris-HCl for the next step.

Following purification of adapter-ligated samples, each sample was spiked with approximately 5x10^-7^ pmoles methylated/unmethylated Enterobacteria phage λ DNA derived by PCR of select regions described elsewhere ([@bib67]); methylated fragments were obtained by *in vitro* methylation using *SssI* methyltransferase. Ten percent sample DNA was reserved as input for quality control purposes (see below). The remaining DNA was incubated with 150 ng anti-5-methylcytidine at 4°C for 15 hrs using automation and manufacturer reagents and protocols (Diagenode). Following immunoprecipitation, DNA was incubated with 1 μg proteinase K (Diagenode) at 55°C for 15 min then 95°C for 15 min. Each sample was subject to quality control using triplicate quantitative PCR (qPCR) reactions with primers designed to amplify methylated/unmethylated control DNA. Reagents (Eurogentec MESABlue qPCR master mix (2×): 6.25 μl; Methylated/Unmethylated Forward and Reverse primer pairs (10 μM): 0.625 μl; water: 4.375 μl; MeDIP or input DNA: 1.25 μl) were mixed on ice and incubated on an ABI 7900 qPCR machine under the following conditions: 95°C for 60 s ; 40 cycles of 95°C for 30 s and 60°C for 60 s then 72°C for 5 min. After confirming enrichment of methylated DNA in the immunoprecipitated fraction (see [@bib67]), DNA was purified using AmpureXP magnetic beads

Following purification, immunoprecipitated DNA samples enriched by adapter-mediated PCR: reagents (water: 2.5 μl; 5x Phusion buffer: 10 μl; NEB dNTPs: 1.5 μl; PCR_PE_1.0 (10 μM stock): 5 μl; PCR_PE\_ 2.0 (10 μM stock): 5 μl; purified DNA: 25 μl; Phusion Polymerase: 1 μl) were mixed on ice in a sterile PCR tube and incubated under the following conditions: 95°C for 30 s; 12 cycles 98°C for 20 s, 65°C for 30 s, 72°C for 30 s, then 72°C for 5 min. Following incubation the samples were purified with Ampure XP purification beads and eluted in 15 μl Tris-HCl. Next, DNA sequencing libraries were size-selected: samples were mixed with 5x loading dye and run out on a 2% TBE agarose gel containing EtBr (1.0 μg/ml), maintaining a minimum of 2 cm between wells. Electrophoresis was performed at 100 volts for 100 min. Following gel electrophoresis, the gel was transferred to a UV transilluminator with a strip of aluminum foil beneath sample wells. Using a clean scalpel, a 300-350 bp slice was excided and transferred to a clean 1.5 ml microcentrifuge tube.

Following gel-excision, samples were purified using QIAGEN Gel Extraction kits: 3 volumes of buffer QG were added to 1 volume gel and vortexed to mix. QG-gel mix was incubated at room temperature until fully dissolved. Next, 10 μl 3 M sodium acetate (pH 5.0) was added and mixed. Next, 1 gel volume of isopropanol was added to the sample and mixed by inversion. The sample was transferred to a MinElute column and centrifuged at 16,000 rpm for 1 min. The flow through was discarded and 500 μl buffer QG was added to the empty sample tube and mixed on a vortex. Next, the 500 μl buffer QG was transferred to MinElute column from the previous step; left to stand for 1 min and centrifuged at max speed for 1 min. The flow through was discarded. Using a pipette, any residual buffer QG from inside the MinElute column was aspirated and discard before washing. To wash, 750 μl PE wash buffer were added to the clean-up column. The column was gently inverted several times to thoroughly wash and centrifuged at max for 1 min. The flow through was discarded and the clean-up column placed back in the same tube. The column was centrifuged for an additional 2 min and visually inspected to ensure that there was no residual solution in the column. The column reservoir was placed in a clean 1.5 ml microcentrifuge tube and DNA eluted by adding 10 μl EB directly onto column the membrane, left to stand for 5 min then centrifuged at max speed for 1 min. 1 μl size selected DNA was assessed on an Agilent Bioanalyzer using DNA High Sensitivity Chips to determine concentration and molarity.

Samples were sequenced on an Illumina GAIIx with 36bp paired-end reads. Downstream bioinformatic processing of reads prior to analysis (i.e., sequence quality control, alignment and filtering) was performed with the MeDUSA pipeline ([@bib72]). To construct the methylation boxplots, chromosomal coordinates were determined for the first exon, the first intron, internal exons, internal introns, and the final exon for each gene, in addition to coordinates corresponding to 2 kb regions up- and downstream of the first and final exons respectively. These coordinates were used to construct 20 equally spaced bins for each such feature per gene. Bam files for each sample were converted into individual wig files ([@bib27]), from which mean levels of methylation were calculated for each bin. These values were then concatenated to investigate larger-scale methylation patterns across gene sets of interest (e.g. non-expressed genes, S/P "early" up-regulated genes, etc.) using in-house Perl scripts and R.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

### Analysis of Gene Expression {#sec5.5.1}

For CTVT-5 and CTVT-6, R/BioConductor ([@bib16]) was used to import the mapped count data and the DESeq library ([@bib1]) was used to normalize the data, estimate variance, filter low expression genes and then predict differentially expressed genes. Specifically, a filtering step was applied to remove low expression genes whose sum of counts across all conditions was within the lowest 40% quantile (9886/24660 genes). Counts for the 14774 remaining genes were then fitted to a negative binomial generalized linear model using a multi-factorial design matrix (tumor stage, dog) and applying a fold-change cut-off of +/- 10 and a Benjamini-Hochberg adjusted p value cut-off of 0.01.

For the 7xx CTVTs, Tximport was used to import the mapped counts data into R and summarize the transcripts-level data into gene level as described (([@bib63]). Counts for 21047 genes were normalized and further analyzed using DESeq2 and the SARTools packages ([@bib30]). Differential gene expression was performed by fitting counts to a negative binomial generalized linear model using a multi-factorial design matrix (design formula of: *regression + regression:dog + regression:time*).

### Heatmaps {#sec5.5.2}

The 1016 genes that passed the cut-off (FC\>10, adj-p\< 0.01) in the old CTVTs and the 1350 genes that passed the same cut-off in the 7xx CTVTs were included in the heatmaps. To generate heatmaps that are consistent across samples, for panel A we calculated log 2 differential expression of the 1016 genes relative to the geometric mean of CTVT-5 B1 and CTVT-6 B1, which corresponds to the mean of the Log2FC. Genes were sorted by relative differential expression of B3. For panel B, we similarly calculated differential expression of the 1350 genes relative to the geometric mean of the five B1 samples. Genes were then sorted by the geometric average relative expression increase in B2s from the three regressing dogs. The raw data used to generate the heatmaps are provided in [Table S2](#mmc3){ref-type="supplementary-material"}. Heatmaps were generated using heatmap.2 function in the package gplots in R (Gregory R. Warnes, Ben Bolker, Lodewijk Bonebakker, Robert Gentleman, Wolfgang Huber Andy Liaw, Thomas Lumley, Martin Maechler, Arni Magnusson, Steffen Moeller, Marc Schwartz and Bill Venables (2016). gplots: Various R Programming Tools for Plotting Data. R package version 3.0.1. <https://CRAN.R-project.org/package=gplots>).

### IPA {#sec5.5.3}

The networks and functional analyses were generated through the use of QIAGEN's Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity){#intref0115}). Genes that reached a cut-off of FC\>10 and an adj-p\< 0.01 were included in the IPA analysis. Comparative analyses were performed using the specific IPA function, selecting individual IPA outputs and clustering pathways based on both statistical significance (Fisher's exact test) and similarity. Diagrams were generated using the Pathdesigner function from the most highly significant and represented networks in the Diseases and Bio-Functions and Canonical Pathways.

Data and Software Availability {#sec5.6}
------------------------------

The accession number for the RNAseq of CTVT-5 and CTVT-6 reported in this paper is ArrayExpress: [E-MTAB-5488](array-express:E-MTAB-5488){#intref0120}.

The accession number for the RNAseq of 7xx CTVTs (761, 765, 766, 772, 774 and 775) reported in this paper is ArrayExpress: [E-MTAB-5889](array-express:E-MTAB-5889){#intref0125}.

The accession number for the MeDIP for CTVT-5, 6 and 17 reported in this paper is ArrayExpress: [E-MTAB-5495](array-express:E-MTAB-5495){#intref0130}.

The accession number for the CTVT genome number 1 reported in ([@bib42]) is European Nucleotide Archive: SAMEA2358413. The accession number for CTVT genome number 2 reported in ([@bib42]) is European Nucleotide Archive SAMEA2358415.

The accession number for the cancer cells transcriptome reported in this paper is ArrayExpress: [E-GEOD-32474](array-express:E-GEOD-32474){#intref0135}.

MeDUSA software: <https://www.ucl.ac.uk/cancer/research/department-cancer-biology/medical-genomics-group/past-projects/medusa-project/medusa>.

CRAN software: [https://CRAN.R](https://cran.r){#intref0145}.

DESeq BioConductor library: <https://bioconductor.org/packages/release/bioc/html/DESeq.html>.

DESeq2 BioConductor library: <http://bioconductor.org/packages/release/bioc/html/DESeq2.html>.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S5Table S1. RNA-Seq CTVTs, Related to Figure 2^a^Biopsy 1 of CTVT-774 did not pass quality controls and could not be included.Table S2. Heatmaps and Venn Diagram, Related to Figure 2Table S3. IPA Results, Related to Figure 3^a^The 1,016 genes that passed the cutoff (FC \> 10 adj-p \< 0.01) constitute the input for the analysis of CTVT-5.^b^The 1,350 genes that passed the cutoff (FC \> 10 adj-p \< 0.01) constitute the input for the analysis of 7xx CTVTs.^c^Comparative analyses were based on statistical significance ranking (--log10 p value, Fisher\'s exact test) and similarity (IPA algorithm).Table S4. Epithelial and Immunological Genes Overlap, Related to Figures 4 and 5Table S5. IPA Core Signatures, Related to Figures 5^a^Statistical significance ranking (--log10 p value, Fisher\'s exact test) and similarity (IPA algorithm) were calculated using the 189 genes that reached statistical significance in the RB2/RB1 versus NRB2/NRB1 comparison in the 7xx CTVTs (see also Table S2 Venn overlap).^b^Statistical significance ranking (--log10 p value, Fisher\'s exact test) and similarity (IPA algorithm) were calculated using the 127 genes forming the core signature of regression (see also Table S2 Venn overlap).Table S6. SNP Analysis, Related to Figure 5^a^Based on detection of \>2 SNPs that match either the host (*Canis familiaris*) or CTVT for the indicated upregulated genes (FC \> 10 adj-p \< 0.01).Table S7. Cell-Cycle Genes, Related to Figure 6Table S8. IPA Core Signature Down, Related to Figure 6^a^Core pathways are grouped based on statistical significance ranking (--log10 p value, Fisher\'s exact test) and similarity (IPA algorithm).Document S2. Article plus Supplemental Information
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[^1]: Lead Contact

[^2]: CTVT-17 could not be analyzed due to poor tissue preservation.

[^3]: NA, not available.

    See also [Figure S1](#mmc1){ref-type="supplementary-material"}.
